Introduction
============

The anterior cruciate ligament (ACL) is an important component to maintain knee-joint stability and is susceptible to injury during competitive sports.[@b1-tcrm-15-487] More than 100,000 patients per year need ACL reconstruction (ACLR) in the US.[@b2-tcrm-15-487] Autologous graft reconstruction is considered the gold-standard treatment, with better tendon--bone healing. However, evidence has shown that autografts of diameter \<8 mm have no guarantee of better prognosis, especially for younger patients.[@b3-tcrm-15-487]

Although allografts on their own have been reported to function similarly to autografts,[@b4-tcrm-15-487] the biomechanics of allografts are influenced by many factors, including irradiation and chemical processing, which is associated with the procession of tendon-bone healing and incorporation. Alvarez-Pinzon et al introduced hybrid-graft surgical techniques to permit the surgeon to customize the size of grafts.[@b5-tcrm-15-487] Allografts have been used in combination with autografts in the hope of increasing inadequate diameters and achieving better outcomes.

In a randomized trial, Li et al prospectively compared autografts, allografts, and hybrid grafts. The results showed similar objective and subjective clinical outcomes for patients undergoing primary ACLR with hybrid grafts or autografts. Both groups of patients had better KT-1000 measurements compared with the γ-irradiated (2.5 Mrad) allograft group.[@b6-tcrm-15-487] Another retrospective comparative study, however, noticed more failure or compromised ACLRs and worse Lysholm and IKDC scores after hybrid-graft reconstruction.[@b7-tcrm-15-487] Jacobs et al later reported more failures in autograft patients, and attributed the better results of hybrid grafts mainly to larger diameter.[@b8-tcrm-15-487] Several studies have been published about hybrid grafts vs autografts, with inconsistent results. Therefore, we conducted this meta-analysis to evaluate the efficacy of hybrid grafts in ACLR.

Methods
=======

Search strategy
---------------

The literature was searched on the Cochrane Library, PubMed, Embase, and ScienceDirect databases for articles published from 1966 to February 2018. Secondary sources were identified from studies cited in the references. No studies were excluded based on the language used. The key search terms were "autografts", "hybrid", "allografts", and "anterior cruciate ligament" in combination with the Boolean operators AND or OR. Also, research on the appraisal reference list was manually reviewed for other potential trials that should be included. The process was iterated until no further articles could be determined. The meta-analysis was based on acknowledged PRISMA guidelines.

Inclusion and exclusion criteria
--------------------------------

Studies were considered eligible for inclusion if they met criteria of: 1) population -- patients with ACLR; 2) intervention -- hybrid graft (autografts augmented by allografts); 3) control -- autograft only; 4) outcome measures -- one or more of graft-failure rate, reoperation rate, complications, postoperative knee score, operation time, and other outcomes reported; and 5) study design -- randomized controlled trials (RCTs) and non-RCTs. We excluded studies without control groups, articles without available full-text versions, and those with no available outcome data.

Data extraction
---------------

Data were extracted from the included trials by two researchers independently (LW and JGC). If article data were incomplete, the complete data were consulted from the corresponding authors of the articles. The following information: first author's name, publication year, intervening measures, outcome measures, sample size, and comparable baselines were extracted. Other relevant parameters were also extracted from individual studies.

Quality assessment
------------------

The methodological index for nonrandomized studies (MINORS) form was used to assess non-RCTs. Quality assessment for RCTs was conducted according to the *Cochrane Handbook for Systematic Reviews of Interventions*. Literature-quality evaluation was conducted by two researchers independently (LW and JGC). Consensus was reached with the senior researcher (JL).

Data analysis and statistical methods
-------------------------------------

RevMan 5.1 (Cochrane Collaboration, Oxford, UK) was used for data analysis. Mean differences (MDs) and 95% CIs were determined for continuous outcomes. Dichotomous data were calculated using ORs and 95% CIs. Heterogeneity was estimated by *I*^2^ based on the standard *χ*^2^ test. When *I*^2^\<50% and *P*\>0.1, no significant heterogeneity existed and a fixed-effect model was used for analysis, while a random-effect model was used when *I*^2^\>50% and *P*\<0.1. Subgroup analysis was performed to investigate sources of heterogeneity.

Results
=======

Search results
--------------

A total of 125 studies were identified as potentially relevant literature reports based on the search strategy. After titles and abstracts had been scanned, 116 reports were excluded according to the eligibility criteria. Kraeutler et al conducted two studies -- in 2016[@b9-tcrm-15-487] and 2018[@b10-tcrm-15-487] -- that both matched eligibility criteria with overlapped data. As such, the later study was included for further data pooling and analysis, because of the larger patient sample. One additional study by Pennock et al was obtained after the reference review.[@b11-tcrm-15-487] Ultimately, eight non-RCTs[@b7-tcrm-15-487],[@b8-tcrm-15-487],[@b10-tcrm-15-487]--[@b15-tcrm-15-487] and one RCT[@b6-tcrm-15-487] were eligible for data extraction and meta-analysis, comprising 322 patients in the hybrid-graft group and 404 patients in the autograft group. The search process is shown in [Figure 1](#f1-tcrm-15-487){ref-type="fig"}.

Study characteristics
---------------------

Demographic characteristics and details concerning literature type are summarized in [Table 1](#t1-tcrm-15-487){ref-type="table"}. Statistically similar baseline characteristics were observed in both groups. Two studies focused on patients \<18 years old.[@b8-tcrm-15-487],[@b11-tcrm-15-487] Most samples were 20--71 years old, while Kraeutler et al included 84 and 119 patients in the hybrid and autograft groups, respectively. However, only 36 matched pairs were evaluated for postoperative knee function. Insufficient autograft size was the main reason for extra allograft augmentation. Cutoff sizes for autografts were \<7.5 mm[@b7-tcrm-15-487] and \<8 mm.[@b6-tcrm-15-487],[@b12-tcrm-15-487]--[@b14-tcrm-15-487] Xu et al added an allograft if the autograft could not restore the insertion site to at least 60% of the cross-sectional area or if the augmentation was able to result in better graft occupancy.[@b15-tcrm-15-487] Graft diameter and length, patient size, growth-plate status, and desired level of sport participation were the bases of decision for another study.[@b11-tcrm-15-487] Semitendinosus tendons were used solely as allografts to augment autograft hamstrings by Darnley et al[@b12-tcrm-15-487] and Jacobs et al.[@b8-tcrm-15-487] Tibialis anterior tendons alone were adopted by Li et al,[@b6-tcrm-15-487] Leo et al,[@b13-tcrm-15-487] Wang et al,[@b14-tcrm-15-487] and Xu et al.[@b15-tcrm-15-487] Both semitendinosus and tibialis anterior tendons were included in Burrus et al[@b7-tcrm-15-487] and Pennock et al.[@b11-tcrm-15-487] Posterior tibialis or peroneus longus tendons were the allografts in Kraeutler et al.[@b10-tcrm-15-487] High-dose irradiation (≥2.5 Mrad) was used in processing of allografts in three studies.[@b6-tcrm-15-487],[@b14-tcrm-15-487],[@b15-tcrm-15-487] Meniscus injury was included in four studies,[@b6-tcrm-15-487],[@b7-tcrm-15-487],[@b11-tcrm-15-487],[@b12-tcrm-15-487] while other studies excluded these patients.

Risk-of-bias assessment
-----------------------

Only one RCT had high methodological quality based on the *Cochrane Handbook for Systematic Reviews of Interventions* ([Figure 2](#f2-tcrm-15-487){ref-type="fig"}). For the eight non-RCTs, the MINORS score ranged from 18 to 24 ([Table 2](#t2-tcrm-15-487){ref-type="table"}). Most studies were retrospective analyses, while only data were prospectively collected in Darnley et al[@b12-tcrm-15-487] and Leo et al.[@b13-tcrm-15-487] Prospective calculation of sample size was also performed in these two studies. No significant publication bias was noticed, based on the funnel plot for revision ([Figure 3](#f3-tcrm-15-487){ref-type="fig"}).

Outcomes of meta-analysis
-------------------------

Six studies reported the diameter of grafts, and pooled data showed which was larger in the hybrid-graft group (MD −1.47, 95% CI 0.95--2.00; *P*=0.0001; [Figure 4](#f4-tcrm-15-487){ref-type="fig"}). The definition was a little different among the studies that reported the rate of failure. Therefore, we report failure, revision, and retear separately in this meta-analysis. Failure rate based on six studies did not show a significantly statistical difference between the two groups (OR 2.13, 95% CI 0.66--6.86; *P*=0.21; [Figure 5](#f5-tcrm-15-487){ref-type="fig"}). However, Jacobs et al[@b8-tcrm-15-487] reported more than double the rate of failure in the autograft group. After exclusion of their cases, a higher failure rate was noticed in the hybrid-graft group (21 of 144) than the autograft group (six of 136), with lower heterogeneity (OR 3.93, 95% CI 1.53--10.07; *P*=0.004). There was no significantly statistical difference in postoperative graft retearing (OR 2.23, 95% CI 0.82--6.10; *P*=0.12) or contralateral tearing (OR 1.00, 95% CI 0.27--3.70; *P*=1.00). Two damaged hybrid grafts and seven compromised ACLRs were also reported by Xu et al[@b15-tcrm-15-487] and Burrus et al.[@b7-tcrm-15-487] Eight non-RCTs reported revision and reoperation. We pooled only data related to grafts. No significant difference was noticed in either revised ACLR (OR 1.05, 95% CI 0.61--1.81; *P*=0.87; [Figure 6](#f6-tcrm-15-487){ref-type="fig"}) or reoperation (OR 1.27, 95% CI 0.77--2.11; *P*=0.35). Subgroup analysis showed that hybrid-graft patients with meniscus injury suffered more revision with lower heterogeneity (OR 4.10, 95% CI 1.28--13.10; *P*=0.02) and reoperation (OR 5.74, 95% CI 2.05--16.03; *P*=0.001). When patients without meniscus injury were investigated, no significant difference existed in either autograft or hybrid-graft patients.

Postoperative knee function was investigated in different studies based on different evaluation systems. Details of meta-analysis results of knee function are illustrated in [Table 3](#t3-tcrm-15-487){ref-type="table"}. Both autografts and hybrid grafts performed similarly in most of these scores. Also, autograft patients had better KT-1000 test scores (MD 0.24, 95% CI 0--0.47; *P*=0.05), Lysholm scores (MD −4.29, 95% CI −8.60--0.03; *P*=0.05), and quality-of-life scores (MD 7.23, 95% CI 0.07--14.38; *P*= 0.05) in the Knee injury and Osteoarthritis Outcome Score (KOOS) measure. Among the five studies reporting Lysholm scores, all patients in Pennock et al were younger than 18 years. Sensitive analysis excluding these cases surprisingly increased the heterogeneity, and again no significant difference existed (*P*=0.13). Subgroup analysis based on meniscus injury or not showed that no significant difference existed in normal-meniscus patients (MD −3.74, *P*=0.43), while the Lysholm score was different between the two groups in meniscus-injury patients (MD −4.74, *P*=0.05).

Discussion
==========

Allograft tendons have been used to augment limited auto-graft size for ACLR in the past few years, and have achieved better results compared with the allograft solely. Based on the included studies, the current meta-analysis showed similar performance in failure, retearing, revision, and reoperation between hybrid-graft and autograft patients.

High heterogeneity existed in results of diameter, graft failure, revision, reoperation, IKDC score, and Lysholm score. For diameter, we did not perform further sensitivity or subgroup analysis, because it mainly depends on the surgeon's preference in our opinion. Jacobs et al reported more than double the rate of failure in the autograft group, and they attributed this to the lower diameters of autografts. In a previous in vitro biomechanical study, Boniello et al showed increasing tensile strength for increased graft diameter.[@b16-tcrm-15-487] Clinical trials also supported the view that the diameter of hamstring autografts should be ≥8 mm to reduce the risk of revision ACLR, especially for younger patients.[@b3-tcrm-15-487] However, grafts showed a sequence of remodeling after implantation in the knee cavity.[@b17-tcrm-15-487] The biomechanics of hybrid grafts changed at different maturity times. It is not appropriate to attribute the better results only to larger diameters. Besides, larger diameters of hybrid grafts behaved significantly differently in revision and knee function in the included studies.

Kraeutler et al also reported much fewer revision cases in allograft patients (2.4% vs 8.4%), and they thought that nonirradiation of the allograft may be one major reason for the better results of hybrid grafts. Some previous studies showed evidence that γ-irradiation can damage the biomechanics of allografts. Using the Kaiser Permanente ACLR Registry, Maletis et al identified 14,015 cases and found a higher risk of revision in allografts with irradiation ≥1.8 Mrad after adjusting for age, sex, and race.[@b18-tcrm-15-487] A meta-analysis also reported a dose-dependent relationship between radiation and decreased mechanical tendon integrity. Low-dose radiation (\<2.5 Mrad) showed graft weakening, with an average 4.3% decrease in load to failure.[@b19-tcrm-15-487] However, some other studies did not support this conception. A study using peroneus tendons at 1.5--2.5 Mrad γ-irradiation did not find major alterations in tendons' biomechanical properties.[@b20-tcrm-15-487] In a systematic review, allograft ACL grafts appeared to be a reasonable alternative to autografts with γ-irradiation \<2.2 Mrad.[@b21-tcrm-15-487] In our nine included studies, high-dose irradiation (2.5 Mrad) was used in three studies and subgroup analysis did not show more failure or revision in hybrid-graft patients.

Previous trials showed that younger patients were associated with more graft failure.[@b22-tcrm-15-487] Patients aged 25 years and younger had a significantly higher failure rate (16.5%) than patients \>25 years (8.3%).[@b23-tcrm-15-487] For each 10-year decrease in age, the odds of graft retearing increase 2.3 times in patients with allograft reconstruction.[@b24-tcrm-15-487] The risk of revision decreased by 7% for each year increase in age.[@b25-tcrm-15-487] Three studies in our study included 32 revisions in 182 patients \<25 years old and 27 revisions in 481 patients \>25 years old. The revision rate decreased from 17.6% to 5.6%, with average age increased from \>25 years to older. However, subgroup analysis showed no significant difference between hybrid grafts and autograft patients in any age range.

Meniscus injury/procedures were reported to be significant predictors of IKDC and KOOS scores 6 years following ACLR.[@b26-tcrm-15-487] Meniscus injury was included in four studies, and meniscus repair or meniscectomy was performed at the same time as ACLR. Subgroup analysis showed that hybrid-graft patients with meniscus injury suffered more revision and reoperation, with lower Lysholm scores. However, no significant difference was noticed in IKDC or Tegner activity scores. With limited detailed description on these procedures, we could not further estimate their effect on ACLR in our included studies.

Limitations
-----------

For full understanding of our research's results, some limitations must be mentioned. First, only one RCT was included, which weakened our power to draw a definitive conclusion. Second, samples were small in most studies, so the relatively larger samples of Jacobs et al and Kraeutler et al had an important influence on the meta-analysis results. Third, many other potential factors can affect ACLR prognosis.

Conclusion
==========

This meta-analysis of the current literature indicates similar performance of hybrid grafts in ACLR, even though hybrid grafts had larger diameters than autograft reconstructions. Irradiation, age at reconstruction, meniscus injury/treatment, hybrid-graft remolding, and other potential factors that influenced failure, revision, or postoperative knee function should be investigated further. Also, more RCTs with more patients and homogeneous design are needed to investigate predictive factors further.
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###### 

Characteristics of included studies

  Study                                Design          Sample size (H/A)   Mean age, years (H/A)   Female (H/A)   Follow-up (H/A)    Allograft source                                Irradiation (Mrad)   Meniscus injury
  ------------------------------------ --------------- ------------------- ----------------------- -------------- ------------------ ----------------------------------------------- -------------------- -----------------
                                                                                                                                                                                                          
  Burrus et al[@b7-tcrm-15-487]        Retrospective   29/29               26.6/27.2               19/19          44.4/48 months     Semitendinosus or tibialis anterior tendons     1.2--1.9             Yes
  Darnley et al[@b12-tcrm-15-487]      Prospective     27/27               20.9/20.9               10/10          2/2 years          Semitendinosus tendon                           \<2.5                Yes
  Jacobs et al                         Retrospective   42/46               15/14.6                 18/26          31.2/46.7 months   Semitendinosus tendon                           1.2--1.9             No
  Kraeutler et al [@b10-tcrm-15-487]   Retrospective   84/119              36.6/35.8               N              3.5/4.7 years      Posterior tibialis or peroneus longus tendons   No                   No
  Leo et al[@b13-tcrm-15-487]          Retrospective   24/71               28.1/26.9               8/25           2/2 years          Tibialis tendons                                No                   No
  Li et al[@b6-tcrm-15-487]            Prospective     31/32               31.6/29.8               13/15          5.9/5.8 years      Tibialis anterior tendons                       2.5                  Yes
  Pennock et al[@b11-tcrm-15-487]      Retrospective   20/20               15.4/15.9               12/13          3/3 years          Semitendinosus or tibialis anterior             0.9--1.3             Yes
  Wang et al[@b14-tcrm-15-487]         Retrospective   28/29               32.6/32.8               19/19          40.6/40.6 months   Tibialis anterior tendons                       2.5                  No
  Xu et al[@b15-tcrm-15-487]           Retrospective   37/31               33.9/32.8               10/15          2/2 years          Tibialis anterior tendons                       2.5                  No

**Abbreviations:** A, autograft; H, hybrid graft; NS, not state.

###### 

Quality assessment for nonrandomized trials

                                               Burrus et al[@b7-tcrm-15-487]   Darnley et al[@b12-tcrm-15-487]   Jacobs et al[@b8-tcrm-15-487]   Kraeutler et al[@b10-tcrm-15-487]   Leo et al[@b13-tcrm-15-487]   Pennock et al[@b11-tcrm-15-487]   Wang et al[@b14-tcrm-15-487]   Xu et al[@b15-tcrm-15-487]
  -------------------------------------------- ------------------------------- --------------------------------- ------------------------------- ----------------------------------- ----------------------------- --------------------------------- ------------------------------ ----------------------------
                                                                                                                                                                                                                                                                                    
  Clearly stated aim                           2                               2                                 2                               2                                   2                             2                                 2                              2
  Inclusion of consecutive patients            2                               2                                 2                               2                                   2                             2                                 2                              2
  Prospective data collection                  0                               2                                 0                               0                                   2                             0                                 0                              0
  End points appropriate to study aims         2                               2                                 2                               2                                   2                             2                                 2                              2
  Unbiased assessment of study end point       2                               2                                 2                               2                                   2                             2                                 2                              2
  Follow-up period appropriate to study aims   2                               2                                 2                               2                                   2                             2                                 2                              2
  Less than 5% loss to follow-up               0                               0                                 2                               0                                   2                             0                                 2                              2
  Prospective calculation of sample size       0                               2                                 0                               0                                   2                             0                                 0                              0
  An adequate control group                    2                               2                                 2                               2                                   2                             2                                 2                              2
  Contemporary groups                          2                               2                                 2                               2                                   2                             2                                 2                              2
  Baseline equivalence of groups               2                               2                                 2                               2                                   2                             2                                 2                              2
  Adequate statistical analyses                2                               2                                 2                               2                                   2                             2                                 2                              2
  Total score                                  18                              22                                20                              18                                  24                            18                                20                             20

###### 

Meta-analysis results of knee function

  Outcome            Studies   Group (hybrid/autograft)   Overall effect   Heterogeneity                
  ------------------ --------- -------------------------- ---------------- ---------------- ------ ---- --------
                                                                                                        
  IKDC               7         212/255                    −0.22            −3.38 to 2.94    0.89   81   0.0001
  Lysholm score      5         145/141                    −4.29            −8.60 to 0.03    0.05   80   0.0004
  Tegner score       4         116/112                    0                −0.27 to 0.28    0.98   0    0.86
  KT-1000 test       3         96/92                      0.24             0--0.47          0.05   51   0.13
  KOOS -- ADL        2         63/63                      0.96             −1.78 to 3.70    0.49   42   0.19
  KOOS -- QOL        2         63/63                      7.23             0.07--14.38      0.05   0    0.46
  KOOS -- sport      2         63/63                      4.65             −2.14 to 11.44   0.18   36   0.21
  KOOS -- symptoms   2         63/63                      3.24             −1.47 to 7.94    0.18   36   0.21
  VAS pain score     2         44/91                      0.14             −0.64 to 0.93    0.72   21   0.26

**Abbreviations:** ADL, activities of daily living; IKDC, International Knee Documentation Committee; KOOS, Knee Injury and Osteoarthritis Outcome Score; KT, knee test; QOL, quality of life.
